The assay was evaluated in relation to specificity, technical performance and as a marker for quantification of fibronectin in cartilage and cancer ex vivo models.
Despite numerous reports of CYFRA21-1 aspecificific marker of multiple malignancies and our evidence of its elevation towards diagnosis in some cases, its performance as a screening marker was very poor and it did not add to CEA when used in combination.
We previously identified CO3-610, a type III collagen neoepitope generated by matrix metalloproteinase (MMP -9, and tested its perforMMP -9anda fibrosis marker in ratestedh bits-duct ligation.
14 Given the important prognostic information made available by knowing MGMT methylation status, in addition to its performance as a predictive marker for response to various therapies outlined in this review, many are calling for MGMT evaluation to be performed routinely on all newly diagnosed GBM patients before adjuvant treatment decisions are made, especially in the elderly.
To improve the efficiency of CNV discovery with SNP arrays, manufacturers have included nongenotyping, nonpolymorphic markers in their designs, which are specifically designed to detect CNVs with greater performance, as well as increasing marker density in CNV regions (Supplementary Table S1).
There is debate within the literature whether procalcitonin is a specific marker of infection, though receiver operating curve (ROC) characteristics in some studies suggest that the performance of procalcitonin as a marker of sepsis is superior to that of CRP [ 22, 23].
To determine whether pyruvate-fortified cardioplegia solution provides cardioprotection superior to lactate-based cardioplegia solutions in patients undergoing elective coronary revascularization, with specific attention to post-surgical recovery of left ventricular performance as well as biochemical markers of ischemic injury.
This meant that simple quantitated levels of hCGβcf per unit volume were so variable that performance as a single screening marker was not substantially greater, in terms of discriminatory power, than existing serum based analysis [ 16- 18].
37 38 39 Although efficient for gene discovery, these are a suboptimal design for evaluating the predictive performance of a marker, as risk information is available only in relative terms and the range of metrics that can be derived to assess predictive performance is more limited than for prospective studies with incident cases of disease.
